Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC


Por: Vergnenegre, A, Massuti B, de Marinis, F, Carcereny, E, Felip, E, Do, P, Miguel Sanchez, J, Paz-Arez, L, Chouaid, C, Rosell, R, Spanish Lung Canc Grp, Italian Assoc Thoracic Oncology and French Lung Canc Grp

Publicada: 1 jun 2016
Resumen:
Introduction: The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal growth factor receptor gene (EGFR)-mutated advanced-stage non-small cell lung cancer (NSCLC) is poorly documented. We therefore conducted a cost-effectiveness analysis of first-line treatment with erlotinib versus standard chemotherapy in European patients with advanced-stage EGFR-mutated NSCLC who were enrolled in the European Erlotinib versus Chemotherapy trial. Methods: The European Erlotinib versus Chemotherapy study was a multicenter, open-label, randomized phase III trial performed mainly in Spain, France, and Italy. We based our economic analysis on clinical data and data on resource consumption (drugs, drug administration, adverse events, and second-line treatments) collected during this trial. Utility values were derived from the literature. Incremental cost-effectiveness ratios were calculated for the first-line treatment phase and for the overall strategy from the perspective of the three participating countries. Sensitivity analyses were performed by selecting the main cost drivers. Results: Compared with standard first-line chemotherapy, the first-line treatment with erlotinib was cost saving ((sic)7807, (sic)17,311, and (sic)19,364 for Spain, Italy and France, respectively) and yielded a gain of 0.117 quality-adjusted life-years. A probabilistic sensitivity analysis indicated that, given a willingness to pay at least (sic)90,000 for 1 quality-adjusted life-year, the probability that a strategy of first-line erlotinib would be cost-effective was 100% in France, 100% in Italy, and 99.8% in Spain. Conclusion: This economic analysis shows that first-line treatment with erlotinib, versus standard chemotherapy, is a dominant strategy for EGFR-mutated advanced-stage NSCLC in three European countries. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Filiaciones:
Vergnenegre, A:
 Limoges Univ Hosp, Thorac Oncol Unit, 2 Ave Martin Luther King, F-87042 Limoges, France

Massuti B:
 Hosp Gen Alicante, Alicante, Spain

de Marinis, F:
 European Inst Oncol, Milan, Italy

Carcereny, E:
 Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

Felip, E:
 Vall dHebron Univ Hosp, Barcelona, Spain

Do, P:
 Ctr Canc Dis Francois Baclesse, Caen, France

Miguel Sanchez, J:
 Hosp Univ 12 Octubre, Madrid, Spain

 MD Anderson, Madrid, Spain

Paz-Arez, L:
 Hosp Univ 12 Octubre, Madrid, Spain

 Inst Invest Biomed Sevilla, Seville, Spain

Chouaid, C:
 Creteil Hosp, Pneumol Unit, Creteil, France

Rosell, R:
 Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
ISSN: 15560864





JOURNAL OF THORACIC ONCOLOGY
Editorial
ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 11 Número: 6
Páginas: 801-807
WOS Id: 000377641700004
ID de PubMed: 26899757

MÉTRICAS